Response at Three Months Is a Good Predictive Factor for Newly Diagnosed Chronic Myeloid Leukemia Patients Treated by Recombinant Interferon-: Presented in part at the 38th annual meeting of the American Society of Hematology, Orlando, FL, December 6-10, 1996.
Blood (1998) 92 (11): 4059–4065.
Currently there are no citedby results. Try again later.
